BRANFORD, Conn., Jan. 18, 2011 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling of its FORE-SIGHT® Absolute Tissue Oximeter to monitor skeletal muscle of infants, children and adolescents weighing between 5 and 50 kg.

The FORE-SIGHT Absolute Tissue Oximeter is used for the continuous, non-invasive monitoring of oxygen saturation of blood in the brain of patients in critical situations. FORE-SIGHT provides highly accurate absolute measurement of  oxygenation levels which allows clinicians to take immediate corrective action when those levels become dangerously low. With this FDA cleared indication, FORE-SIGHT can now be clinically utilized for use on both brain and skeletal muscle.

The addition of non-cerebral monitoring represents a critical step in the evolution of this innovative technology. "The expanded application of skeletal muscle to our indications for use will allow improved monitoring of critically ill patients. This monitoring can aid clinicians to quickly detect ischemic threats, such as those associated with anemia, low-cardiac output or shock," stated Thomas M. Patton, President and CEO of CASMED. 

"Cerebral and skeletal muscle oximetry with FORE-SIGHT can provide an important adjunct to conventional monitoring that allows for continuous, non-invasive and earlier assessment of perfusion abnormalities," Mr. Patton added.  "Because  patient care and innovation are core values of CASMED, we are excited about the opportunities that this new application will offer the medical community and for the expanded application of our FORE-SIGHT technology."

About CASMED^® - Monitoring What's Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Tissue Oximeter provides absolute, non-trended, simultaneous measurements of both brain and body.

The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Absolute Tissue Oximeter, the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.

For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.

The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, customer acceptance of the products in the market, the introduction of competitive products and product development, potential litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.